These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9538519)

  • 41. [Angiotensin-II receptor blockers].
    Metelitsa VI
    Ter Arkh; 1996; 68(8):64-7. PubMed ID: 9019837
    [No Abstract]   [Full Text] [Related]  

  • 42. Angiotensin II receptor antagonists: the prototype losartan.
    Schaefer KL; Porter JA
    Ann Pharmacother; 1996 Jun; 30(6):625-36. PubMed ID: 8792950
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients.
    Goldberg MR; Bradstreet TE; McWilliams EJ; Tanaka WK; Lipert S; Bjornsson TD; Waldman SA; Osborne B; Pivadori L; Lewis G
    Hypertension; 1995 Jan; 25(1):37-46. PubMed ID: 7843751
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
    Schmidt B; Schieffer B
    J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
    [No Abstract]   [Full Text] [Related]  

  • 45. FLEXS: a method for fast flexible ligand superposition.
    Lemmen C; Lengauer T; Klebe G
    J Med Chem; 1998 Nov; 41(23):4502-20. PubMed ID: 9804690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Non-peptide antagonists to angiotensin II receptors. A review].
    Schambye HT; Hjorth SA; Schwartz TW
    Ugeskr Laeger; 1993 Nov; 155(44):3558-62. PubMed ID: 8236577
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems.
    Burnier M; Pechère-Bertschi A; Nussberger J; Waeber B; Brunner HR
    Am J Kidney Dis; 1995 Jul; 26(1):108-15. PubMed ID: 7611241
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
    Vanderheyden PM; Fierens FL; Vauquelin G
    Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist.
    Duncia JV; Carini DJ; Chiu AT; Johnson AL; Price WA; Wong PC; Wexler RR; Timmermans PB
    Med Res Rev; 1992 Mar; 12(2):149-91. PubMed ID: 1619965
    [No Abstract]   [Full Text] [Related]  

  • 51. Nonpeptide angiotensin II receptor antagonists: in vivo inhibition of [125I-Sar1,Ile8]angiotensin II binding by losartan, EXP597 and L-159,282 in rats.
    Wong PC; Herblin WF; Barbera FA; Bernard R; Bozarth TA; Watson CA; Gibson RE
    Clin Exp Hypertens; 1996 Feb; 18(2):189-200. PubMed ID: 8869000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Classification of ligand molecules in PDB with graph match-based structural superposition.
    Shionyu-Mitsuyama C; Hijikata A; Tsuji T; Shirai T
    J Struct Funct Genomics; 2016 Dec; 17(4):135-146. PubMed ID: 28012138
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of angiotensin II type-1 and type-2 receptor antagonists on angiotensin II-induced IP3 generation in cardiomyocytes.
    Goutsouliak V; Rabkin SW
    Gen Pharmacol; 1998 Mar; 30(3):367-72. PubMed ID: 9510088
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme.
    Campbell DJ; Kladis A; Valentijn AJ
    J Cardiovasc Pharmacol; 1995 Aug; 26(2):233-40. PubMed ID: 7475048
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The conformation and activity relationship of benzofuran type of angiotensin II receptor antagonists.
    Yoo SE; Kim SK; Lee SH; Kim NJ; Lee DW
    Bioorg Med Chem; 2000 Sep; 8(9):2311-6. PubMed ID: 11026543
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of AT1 angiotensin-receptor blockade on structure and function of small arteries in SHR.
    Li JS; Sharifi AM; Schiffrin EL
    J Cardiovasc Pharmacol; 1997 Jul; 30(1):75-83. PubMed ID: 9268224
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inhibitory effects of angiotensin II receptor antagonists and leukotriene receptor antagonists on the transport of human organic anion transporter 4.
    Yamashita F; Ohtani H; Koyabu N; Ushigome F; Satoh H; Murakami H; Uchiumi T; Nakamura T; Kuwano M; Tsujimoto M; Sawada Y
    J Pharm Pharmacol; 2006 Nov; 58(11):1499-505. PubMed ID: 17132213
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Action of AT1 receptor antagonists on angiotensin II-induced tone in human isolated subcutaneous resistance arteries.
    Garcha RS; Sever PS; Hughes AD
    Br J Pharmacol; 1999 Aug; 127(8):1876-82. PubMed ID: 10482919
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist.
    Wong PC; Tam SW; Herblin WF; Timmermans PB
    Eur J Pharmacol; 1991 Apr; 196(2):201-3. PubMed ID: 1651874
    [No Abstract]   [Full Text] [Related]  

  • 60. Effects of BAY 10-6734 (Embusartan), a new angiotensin II type I receptor antagonist, on vascular smooth muscle cell growth.
    Iouzalen L; Stepien O; Marche P
    J Pharmacol Exp Ther; 1999 Apr; 289(1):181-7. PubMed ID: 10087002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.